Back matter
References
Numbered by entry, in the order the entries appear. Sources added for this edition (the letters, the primer, the thyroid note, the B12 note, the F. prausnitzii pipeline and the label checks) were checked in September 2026. Always verify your own facts, and write to help@supplementsforibd.com if you find an error.
A-01 · Curcumin
- Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4(12):1502–1506.
- Lang A, Salomon N, Wu JCY, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol 2015;13(8).
- Sugimoto K, Ikeya K, Bamba S, et al. Highly bioavailable curcumin derivative ameliorates Crohn's disease symptoms: a randomized, double-blind, multicenter study. J Crohns Colitis 2020;14(12):1693–1701.
- Kedia S, Bhatia V, Thareja S, et al. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: results from a randomized double blind placebo controlled trial. World J Gastrointest Pharmacol Ther 2017;8(2):147–154.
- Garg SK, Ahuja V, Sankar MJ, Kumar A, Moss AC. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;(10):CD008424.
- Coelho MR, Romi MD, Ferreira DMTP, Zaltman C, Soares-Mota M. The use of curcumin as a complementary therapy in ulcerative colitis: a systematic review of randomized controlled clinical trials. Nutrients 2020;12(8):2296.
- Safety and efficacy of curcumin in the treatment of ulcerative colitis: an updated systematic review and meta-analysis of randomized controlled trials. 2024 (Elsevier; risk ratio for clinical remission 2.10 at ≤8 weeks).
- Singla V, Pratap Mouli V, Garg SK, et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis: a randomized, placebo-controlled, pilot study. J Crohns Colitis 2014. (n = 45; cited in Frontiers/ScienceDirect polyphenol reviews.)
- Kurtar KA, et al. Effects of Mediterranean diet, curcumin, and resveratrol on mild-to-moderate active ulcerative colitis: a multicenter randomized clinical trial. Nutrients 2024;16(10):1504.
A-02 · Quercetin
- Lu SY, Dan L, Sun S, Fu T, Chen J. Dietary quercetin intake is associated with lower ulcerative colitis risk but not Crohn's disease in a prospective cohort study and in vivo experiments. Food Funct 2024. doi:10.1039/d3fo05391a. (UK Biobank, n = 187,709.)
- Wang T, Lu SY, Dan L, et al. Higher dietary quercetin intake is associated with lower risk of adverse outcomes among individuals with inflammatory bowel disease in a prospective cohort study. J Nutr 2024;154(6):1861–1868.
- Biological activities underlying the therapeutic effect of quercetin on inflammatory bowel disease. 2022. PMC9338876.
- Indol-3-carbinol and quercetin ameliorate chronic DSS-induced colitis in C57BL/6 mice by AhR-mediated anti-inflammatory mechanisms. 2021. PMC7956562.
- Efficacy and mechanism of quercetin in the treatment of experimental colitis using network pharmacology analysis. Molecules 2023;28(1):146.
- ClinicalTrials.gov NCT05371340 (quercetin 500 mg/day); NCT03989271 (quercetin 2,000 mg/day). Registry entries.
A-03 · Omega-3 EPA/DHA
- Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med 1996;334(24):1557–1560.
- Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA 2008;299(14):1690–1697.
- Scaioli E, Sartini A, Bellanova M, et al. Eicosapentaenoic acid reduces fecal levels of calprotectin and prevents relapse in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2018;16(8):1268–1275.e2.
- Cabré E, Mañosa M, Gassull MA. Omega-3 fatty acids and inflammatory bowel diseases: a systematic review. Br J Nutr 2012;107(Suppl 2):S240–S252. (Conclusion: no firm recommendation possible.)
- Astore C, Nagpal S, Gibson G. Mendelian randomization indicates a causal role for omega-3 fatty acids in inflammatory bowel disease. Int J Mol Sci 2022;23(22):14380; and a 2023 mediation Mendelian randomization study (Metabolites 2023;13(10):1041) linking genetically higher EPA to lower IBD risk (OR 0.78).
- Prossomariti A, Scaioli E, Piazzi G, et al. Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis. Sci Rep 2017;7(1):7458.
A-04 · Serum-derived bovine immunoglobulins
- Shafran I, Burgunder P, Wei D, Young HE, Klein G, Burnett BP. Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin. Therap Adv Gastroenterol 2015. doi:10.1177/1756283X15593693.
- Liaquat H, Ashat M, Stocker A, et al. Clinical efficacy of serum-derived bovine immunoglobulin in patients with refractory inflammatory bowel disease. Am J Med Sci 2018;356(6):531–536.
- Wilson D, Evans M, Weaver E, Shaw AL, Klein GL. Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol 2013;6:49–60.
- Serum bovine immunoglobulins improve inflammation and gut barrier function in persons with HIV and enteropathy on suppressive ART. 2019. PMC6508431.
- Soriano RA, Ramos-Soriano AG. Clinical and pathologic remission of pediatric ulcerative colitis with serum-derived bovine immunoglobulin added to the standard treatment regimen. Case Rep Gastroenterol 2017;11(2):335–343.
- Bovine immunoglobulin/protein isolate binds pro-inflammatory bacterial compounds and prevents immune activation in an intestinal co-culture model. PLoS One 2015. PMC4382133.
- Pérez-Bosque A, Miró L, Maijó M, et al. Oral serum-derived bovine immunoglobulin/protein isolate has immunomodulatory effects on the colon of mice that spontaneously develop colitis. PLoS One 2016;11(5):e0154823.
- Valentin N, Camilleri M, Carlson P, et al. Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome. Physiol Rep 2017;5(5):e13170.
- Hazan S, Bao G, Vidal A, Sfera A. Gut microbiome alterations following oral serum-derived bovine immunoglobulin administration in the management of dysbiosis. Cureus 2024;16(12):e75884.
- ClinicalTrials.gov NCT04223518 (SBI in children and young adults with IBD); NCT02358694 (SBI in pediatric IBS-D). Registry entries.
- EnteraGam (serum-derived bovine immunoglobulin/protein isolate) product information: no significant interactions with commonly prescribed medications reported. Entera Health.
A-05 · Vitamin D3
- Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn's disease – a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010;32(3):377–383.
- Effectiveness of vitamin D supplementation on disease course in inflammatory bowel disease patients: systematic review with meta-analysis. Inflamm Bowel Dis 2024;30(2):281–291. (RR 0.64; Crohn's in remission RR 0.47.)
- de Bruyn JR, Bossuyt P, Ferrante M, et al. High-dose vitamin D does not prevent postoperative recurrence of Crohn's disease in a randomized placebo-controlled trial. Clin Gastroenterol Hepatol 2021;19(8):1573–1582.e5.
- Li J, Chen N, Wang D, Zhang J, Gong X. Efficacy of vitamin D in treatment of inflammatory bowel disease: a meta-analysis. Medicine (Baltimore) 2018;97(46):e12662. (Vitamin D reduced relapse rate; no difference between high and low doses on relapse.)
- Guzman-Prado Y, et al. Vitamin D therapy in adults with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2020. (Cited as reference 26 of the 2024 IBD meta-analysis; did not assess relapse.)
- Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology 2012;142(3):482–489.
- Efficacy and safety of vitamin D adjuvant therapy for ulcerative colitis: a meta-analysis. 2022. PMC9328974. (Vitamin D plus mesalazine vs mesalazine: clinical efficacy OR 4.07, lower Mayo scores; mostly Chinese trials.)
C-01 · Bilberry / anthocyanins
- Biedermann L, Mwinyi J, Scharl M, et al. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis: an open pilot study. J Crohns Colitis 2013;7(4):271–279.
- Roth S, Spalinger MR, Gottier C, et al. Bilberry-derived anthocyanins modulate cytokine expression in the intestine of patients with ulcerative colitis. PLoS One 2016;11(5):e0154817.
- A multi-center randomized, double-blind, placebo-controlled, parallel group, phase IIa study to evaluate the efficacy, safety and tolerability of an anthocyanin rich extract (ACRE) in patients with ulcerative colitis. medRxiv 2024 (preprint). doi:10.1101/2024.07.19.24310589.
C-02 · Boswellia serrata
- Holtmeier W, Zeuzem S, Preiss J, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy. Inflamm Bowel Dis 2011;17(2):573–582.
- Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 2001;39(1):11–17.
- Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 2001;67(5):391–395.
- Madisch A, Miehlke S, Eichele O, Mrwa J, Bethke B, Kuhlisch E, et al. Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis 2007;22(12):1445–1451. (n = 31; 400 mg three times daily for 6 weeks; clinical remission 63.6% vs 26.7% per protocol, p = 0.04; 43.8% vs 26.7% intention-to-treat, p = 0.25; no effect on histology or quality of life.)
C-03 · Andrographis paniculata
- Triantafyllidi A, Xanthos T, Papalois A, Triantafillidis JK. Herbal and plant therapy in patients with inflammatory bowel disease. Ann Gastroenterol 2015;28(2):210–220.
- Tang T, Targan SR, Li ZS, Xu C, Byers VS, Sandborn WJ. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis, a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther 2011;33(2):194–202.
- Sandborn WJ, Targan SR, Byers VS, et al. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol 2013;108(1):90–98. (224 patients; response 60% on 1,800 mg/day vs 40% placebo; remission 38% vs 25%, not significant.)
C-04 · Green tea / EGCG
- Dryden GW, Lam A, Beatty K, Qazzaz HH, McClain CJ. A pilot study to evaluate the safety and efficacy of an oral dose of (−)-epigallocatechin-3-gallate–rich Polyphenon E in patients with mild to moderate ulcerative colitis. Inflamm Bowel Dis 2013;19(9):1904–1912.
- Refractory pouchitis improves after administration of the green tea polyphenol EGCG: a retrospective review. Int J Colorectal Dis 2017. doi:10.1007/s00384-017-2906-5.
C-05 · Ginger
- Nikkhah-Bodaghi M, Maleki I, Agah S, Hekmatdoost A. Zingiber officinale and oxidative stress in patients with ulcerative colitis: a randomized, placebo-controlled, clinical trial. Complement Ther Med 2019;43:1–6.
- Natural antioxidant substances improve oxidative stress and alleviate ulcerative colitis: a meta-analysis of randomized controlled trials. Sci Rep 2025. PMC12753649.
C-06 · Resveratrol
- Samsami-kor M, Daryani NE, Asl PR, Hekmatdoost A. Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res 2015. PMID 26002728.
- Samsamikor M, Daryani NE, Asl PR, Hekmatdoost A. Resveratrol supplementation and oxidative/anti-oxidative status in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res 2016;47(4):304–309. (56 patients, 500 mg/day, six weeks; SOD and TAC up, MDA down; summarized in the 2021 antioxidant systematic review.)
- Kurtar KA, et al. Effects of Mediterranean diet, curcumin, and resveratrol on mild-to-moderate active ulcerative colitis: a multicenter randomized clinical trial. Nutrients 2024;16(10):1504.
- Nunes S, Danesi F, Del Rio D, Silva P. Resveratrol and inflammatory bowel disease: the evidence so far. Nutr Res Rev 2018.
C-07 · Mastic gum
- Gioxari A, Kaliora AC, Papalois A, Agrogiannis G, Triantafillidis JK, Andrikopoulos NK. Pistacia lentiscus resin regulates intestinal damage and inflammation in trinitrobenzene sulfonic acid-induced colitis. J Med Food 2011;14(11):1403–1411.
- ClinicalTrials.gov NCT02796339. A study on the effectiveness of a nutritional supplement with natural Mastiha in inflammatory bowel diseases. Registry entry.
- Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Chios mastic treatment of patients with active Crohn's disease. World J Gastroenterol 2007;13(5):748–753.
C-08 · Melatonin
- Chojnacki C, Wisniewska-Jarosinska M, Walecka-Kapica E, Klupinska G, Jaworek J, Chojnacki J. Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol 2011;62(3):327–334. (Mesalazine 2 g/day plus melatonin 5 mg at bedtime, 12 months.)
C-10 · N-acetylcysteine (NAC)
- Guijarro LG, Mate J, Gisbert JP, et al. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. World J Gastroenterol 2008;14(18):2851–2857.
- Effect of N-acetylcysteine on remission maintenance in patients with ulcerative colitis: a randomized, double-blind controlled clinical trial. (Retrieved as a citing study of Guijarro 2008; details to be added.)
C-13 · CoQ10
- Natural antioxidant substances improve oxidative stress and alleviate ulcerative colitis: a meta-analysis of randomized controlled trials. Sci Rep 2025. PMC12753649. (Includes a 2021 double-blind RCT of CoQ10 200 mg/day for 8 weeks in UC, n = 86.)
C-14 · Rutin
- Polyphenols and the potential mechanisms of their therapeutic benefits against inflammatory bowel diseases. J Funct Foods 2022. doi:10.1016/j.jff.2022.105181 (ScienceDirect S1756464622002511).
C-15 · Sulforaphane
- The role of dietary nutrients in inflammatory bowel disease. Front Immunol 2018;9:3183.
C-16 · Reishi
- Dietary polyphenols ameliorate inflammatory bowel diseases: advances and future perspectives to maximize their nutraceutical applications. Phytochem Rev 2023. doi:10.1007/s11101-023-09866-z.
C-18 · Lion's mane
- Tursi A, D'Avino A, Brandimarte G, et al. Enhancing oral 5-ASA effectiveness in mild-to-moderate ulcerative colitis through an H. erinaceus-based nutraceutical add-on multi-compound: the HERICIUM-UC two-arm multicentre retrospective study. Pharmaceutics 2024;16(9):1133.
C-22 · Milk thistle
- Rastegarpanah M, Malekzadeh R, Vahedi H, et al. A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis. Chin J Integr Med 2015;21(12):902–906. (80 patients in remission; 140 mg/day for six months; hemoglobin and ESR improved; 35 of 38 vs 21 of 32 remained in remission.)
D-01 · Akkermansia muciniphila
- Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 2019;25(7):1096–1103. (Safety and tolerability of live and pasteurized A. muciniphila in humans.)
- Akkermansia muciniphila: the state of the art, 18 years after its first discovery. Front Gastroenterol 2022. doi:10.3389/fgstr.2022.1024393.
- Akkermansia muciniphila supplementation alters inflammatory profiles across diverse models of colitis. Sci Rep 2026. doi:10.1038/s41598-026-60105-9.
- Strain-dependent efficacy of pasteurized Akkermansia muciniphila in alleviating colitis reveals AKK2645 restores immune and microbial homeostasis. 2025. PMC13455503.
D-02 · Saccharomyces boulardii
- Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45(7):1462–1464.
- Bourreille A, Cadiot G, Le Dreau G, et al. Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol 2013;11(8):982–987.
D-04 · Multi-strain Lactobacillus / Bifidobacterium
- Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 2005;54(2):242–249. (Listed in the 2024 Applied Sciences systematic review of phytochemical and nutritional RCTs in IBD.)
- Therapeutic effects of probiotics on ulcerative colitis: review with tables of single- and multi-strain trials. Front Microbiol 2023;14:1211271.
D-05 · Lactobacillus reuteri
- Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012;35(3):327–334. (n = 40; Mayo score 8.6 to 3.2 vs no change on placebo; mucosal IL-10 up, TNF-alpha down.)
D-06 · Lactobacillus plantarum 299v
- Therapeutic effects of probiotics on ulcerative colitis. Front Microbiol 2023;14:1211271. (Strain-level table.)
D-07 · Psyllium
- Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999;94(2):427–433.
- Are all dietary fibers equal for patients with inflammatory bowel disease? A systematic review of randomized controlled trials. Nutr Rev 2022. PMC8990763.
D-08 · Partially hydrolyzed guar gum
- Are all dietary fibers equal for patients with inflammatory bowel disease? A systematic review of randomized controlled trials. Nutr Rev 2022. PMC8990763.
D-09 · Inulin / FOS
- Casellas F, Borruel N, Torrejón A, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther 2007;25(9):1061–1067.
- Prebiotics for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2023;CD015084.
D-10 · Galacto-oligosaccharides (GOS)
- Are all dietary fibers equal for patients with inflammatory bowel disease? A systematic review of randomized controlled trials. Nutr Rev 2022. PMC8990763.
D-11 · Resistant starch
- Are all dietary fibers equal for patients with inflammatory bowel disease? A systematic review of randomized controlled trials. Nutr Rev 2022. PMC8990763.
D-13 · Acacia gum
- Are all dietary fibers equal for patients with inflammatory bowel disease? A systematic review of randomized controlled trials. Nutr Rev 2022. PMC8990763.
E-01 · Berberine
- Efficacy and safety of berberine plus 5-ASA for ulcerative colitis: a systematic review and meta-analysis. PLoS One 2024. PMC11379390. (10 RCTs, 952 patients; clinical efficacy RR 1.22.)
- ClinicalTrials.gov NCT02365480. Berberine chloride in preventing colorectal cancer in patients with ulcerative colitis in remission (Moss AC, principal investigator). Registry entry and protocol.
E-02 · Oregano oil
- Roberts CL, et al. Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010;59(10):1331–1339. (Context: dietary antimicrobials and the AIEC hypothesis.)
E-04 · Wormwood (Artemisia)
- Omer B, Krebs S, Omer H, Noor TO. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study. Phytomedicine 2007;14(2–3):87–95.
- Krebs S, Omer TN, Omer B. Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease: a controlled clinical trial. Phytomedicine 2010;17(5):305–309.
- Rahimi R, Nikfar S, Abdollahi M. Induction of clinical response and remission of inflammatory bowel disease by use of herbal medicines: a meta-analysis. World J Gastroenterol 2013;19(34):5738–5749. (Two A. absinthium trials, n = 60; relative risk for clinical remission 27; summarized in the Drugs.com wormwood monograph.)
F-01 · L-glutamine
- Benjamin J, Makharia G, Ahuja V, et al. Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn's disease: a randomized controlled trial. Dig Dis Sci 2012;57(4):1000–1012.
- Den Hond E, Hiele M, Peeters M, Ghoos Y, Rutgeerts P. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. JPEN J Parenter Enteral Nutr 1999;23(1):7–11. PMID 9888411.
- Akobeng AK, et al. Glutamine for induction of remission in Crohn's disease. Cochrane Database Syst Rev (two small studies; insufficient evidence).
- A systematic review and meta-analysis of clinical trials on the effects of glutamine supplementation on gut permeability in adults. Amino Acids 2024. PMID 39397201. (10 studies, 352 participants; no overall effect.)
F-02 · Butyrate
- Sodium butyrate effectiveness in children and adolescents with newly diagnosed inflammatory bowel diseases: randomized placebo-controlled multicenter trial. Nutrients 2022. PMC9414716. (150 mg twice daily add-on, 12 weeks, n = 72 completing.)
F-03 · Creatine
- Wallimann T, Hall CHT, Colgan SP, Glover LE. Creatine supplementation for patients with inflammatory bowel diseases: a scientific rationale for a clinical trial. Nutrients 2021;13(5):1429.
- ClinicalTrials.gov NCT02463305. Therapeutic modulation of the intestinal creatine kinase system in IBD (University of Colorado; pilot RCT of creatine 21 g/day in UC). Status: withdrawn, 0 participants.
F-04 · Aloe vera (inner leaf)
- Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther 2004;19(7):739–747.
- ClinicalTrials.gov NCT04753775. Randomized, double-blind, placebo-controlled trial of enema aloe vera gel in active ulcerative proctosigmoiditis (Ospedale Sandro Pertini, Rome). Registry entry.
F-05 · Zinc carnosine
- Mahmood A, FitzGerald AJ, Marchbank T, et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut 2007;56(2):168–175. (Crossover trial, 10 volunteers: 37.5 mg twice daily prevented the threefold rise in gut permeability caused by indomethacin.)
- Davison G, Marchbank T, March DS, Thatcher R, Playford RJ. Zinc carnosine works with bovine colostrum in truncating heavy exercise-induced increase in gut permeability in healthy volunteers. Am J Clin Nutr 2016;104(2):526–536.
F-06 · N-acetylglucosamine (NAG)
- Salvatore S, Heuschkel R, Tomlin S, et al. A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease. Aliment Pharmacol Ther 2000;14(12):1567–1579. (8 of 12 children with treatment-resistant IBD improved; histology and glycosaminoglycan layer improved.)
- N-acetylglucosamine for treatment of inflammatory bowel disease. Natural Medicine Journal 2021/2022 (open-label adult series, 6 g/day for four weeks; 30–65% reported symptom improvement).
F-07 · Bovine colostrum
- Khan Z, Macdonald C, Wicks AC, et al. Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study. Aliment Pharmacol Ther 2002;16(11):1917–1922.
- Colostrum therapy for human gastrointestinal health and disease. Nutrients 2021. PMC8228205.
F-08 · Phosphatidylcholine
- Stremmel W, Merle U, Zahn A, Autschbach F, Hinz U, Ehehalt R. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 2005;54(7):966–971.
- Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. J Clin Gastroenterol 2010;44(5):e101–e107.
- Stremmel W, Vural H, et al. Delayed-release phosphatidylcholine is effective for treatment of ulcerative colitis: a meta-analysis. Dig Dis 2021;39(5):508. (3 RCTs, 160 patients; remission OR 9.68.)
- Modified-release phosphatidylcholine (LT-02) for ulcerative colitis: two double-blind, randomized, placebo-controlled trials. Clin Gastroenterol Hepatol 2023. PMID 37806372. (PCG-2 terminated for futility; 466 randomized; deep remission 13.5% placebo vs 14.2% and 9.7% on LT-02.)
F-09 · Collagen peptides
- Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. Nutrients 2023. PMC10489664. (Protein and nutritional status in IBD.)
F-10 · Slippery elm
- Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther 2002;16(2):197–205. (Slippery elm, tormentil, devil's claw and wei tong ning scavenged oxygen radicals in inflamed UC biopsies, comparable to 5-ASA.)
F-12 · DGL licorice
- Langhorst J, Wulfert H, Lauche R, et al. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis 2015;9(1):86–106.
F-13 · Chamomile
- Langhorst J, Varnhagen I, Schneider SB, et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis, a double-blind, double-dummy study. Aliment Pharmacol Ther 2013;38(5):490–500. (Abstract: BMC Complement Altern Med 2012;12(Suppl 1):O27.)
- Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ, Korzenik J. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis 2015;9(1):86–106. (Best herbal evidence: Plantago ovata and curcumin in UC maintenance, wormwood in Crohn's.)
G-01 · BPC-157
- Sikiric P, Seiwerth S, Skrtic A, et al. Stable gastric pentadecapeptide BPC 157 as a therapy and safety key: a special beneficial pleiotropic effect controlling and modulating angiogenesis and the NO-system. Pharmaceuticals 2025;18(6):928.
- Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. 2025. PMC11859134. (Not approved by FDA or other regulators; human data insufficient.)
- Operation Supplement Safety (US Department of Defense). BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products. 2024.
- STAT News, 3 February 2026. BPC-157: the peptide with big claims and scant evidence. (Nearly all data from one Croatian group; UC enema trials by PLIVA in the 2000s never fully published; a 2015 oral safety trial's registry data were withdrawn before review.)
G-02 · KPV
- Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. 2025. PMC11859134. (Context on oral peptide regulation.)
H-01 · Peppermint oil (enteric-coated)
- Alammar N, Wang L, Saberi B, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. BMC Complement Altern Med 2019;19:21. (Enteric-coated peppermint oil vs placebo: global symptoms RR 2.39; NNT 3.)
- Ingrosso MR, et al. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther 2022. (10 RCTs, 1,030 patients; superior to placebo, more adverse events, very low quality of evidence.)
- Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol 2014;48(6):505–512.
H-02 · Broad-spectrum digestive enzymes
- Pancreatic involvement in inflammatory bowel disease: a review. 2018. PMC6135003. (Fecal-elastase study: exocrine pancreatic insufficiency in 14% of Crohn's and 22% of UC patients.)
- Can IgG4 levels identify the ulcerative colitis subtype of inflammatory bowel disease? Cross-sectional study, 2016. PMC5051143. (Exocrine pancreatic insufficiency in 17.8% of 56 IBD patients; literature range 8–50%.)
H-03 · Papain (papaya enzyme)
- Kane S, Goldberg MJ. Use of bromelain for mild ulcerative colitis. Ann Intern Med 2000;132(8):680.
H-04 · Bromelain
- Kane S, Goldberg MJ. Use of bromelain for mild ulcerative colitis. Ann Intern Med 2000;132(8):680. (Two patients achieving clinical and endoscopic remission.)
- Onken JE, et al. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol 2008. PMID 18160345.
- ClinicalTrials.gov NCT06351696. The effects of bromelain supplement in patients with ulcerative colitis (Shahid Beheshti University; recruiting).
H-07 · Diamine oxidase (DAO)
- Schnedl WJ, et al. Diamine oxidase supplementation improves symptoms in patients with histamine intolerance. Food Sci Biotechnol 2019;28(6):1779–1784.
I-01 · Tryptophan
- Nikolaus S, Schulte B, Al-Massad N, et al. Increased tryptophan metabolism is associated with activity of inflammatory bowel diseases. Gastroenterology 2017;153(6):1504–1516.e2. (535 IBD patients; serum tryptophan lower and inversely correlated with disease activity.)
- Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 2018; and Microbial tryptophan catabolites in health and disease, Nat Commun 2018;9:3294.
J-01 · Iron
- Dignass AU, Gasche C, Bettenworth D, et al.; European Crohn's and Colitis Organisation. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015;9(3):211–222. (Screen every 3 months in active disease, 6–12 in remission; ferritin cut-offs 30 and 100 µg/L; intravenous iron first-line in active disease, oral intolerance, or Hb below 10 g/dL.)
- Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007;13(12):1545–1553.
- Safety and efficacy of ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease: a systematic review. 2025. PMC11743820. (Up to 90% of oral iron is unabsorbed and can oxidize in the gut.)
J-02 · Vitamin B12
- Scholten AM, et al. Surplus vitamin B12 use does not reduce fatigue in patients with irritable bowel syndrome or inflammatory bowel disease: a randomized double-blind placebo-controlled trial. Clin Nutr ESPEN 2018 (listed in a 2025 integrative review of pharmacological treatments for IBD fatigue).
J-03 · Folate (B9)
- Antioxidant and anti-inflammatory phytochemicals for the treatment of inflammatory bowel disease: a systematic review. Appl Sci 2024;14(5):2177. (Table of RCTs 1993–2021 in IBD.)
J-04 · Zinc
- Siva S, Rubin DT, Gulotta G, Wroblewski K, Pekow J. Zinc deficiency is associated with poor clinical outcomes in patients with inflammatory bowel disease. Inflamm Bowel Dis 2017;23(1):152–157. (More hospitalizations, surgeries and complications; normalization improved outcomes.)
- Almuhaya H, et al. Prevalence and impact of zinc deficiency on clinical outcomes in inflammatory bowel disease. Nutrients 2025;17(21):3378. (45.6% of 447 patients deficient.)
J-05 · Magnesium
- Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. Nutrients 2023. PMC10489664.
J-06 · Vitamin A
- Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. Nutrients 2023. PMC10489664.
J-07 · Calcium
- Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. Nutrients 2023. PMC10489664.
J-08 · Thiamine (B1)
- Bager P, Hvas CL, Rud CL, Dahlerup JF. Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease. Aliment Pharmacol Ther 2021;53(1):79–86.
- Bager P, et al. Long-term maintenance treatment with 300 mg thiamine for fatigue in patients with IBD: results from an open-label extension. 2022. (300 mg/day did not maintain the effect.)
- Costantini A, Pala MI. Thiamine and fatigue in inflammatory bowel diseases: an open-label pilot study. J Altern Complement Med 2013;19(8):704–708.
J-09 · Riboflavin (B2)
- von Martels JZH, Bourgonje AR, Klaassen MAY, et al. Riboflavin supplementation in patients with Crohn's disease (the RISE-UP study). J Crohns Colitis 2020. (Cited in Nutrients 2023 micronutrient review.)
J-10 · Niacin (B3)
- Wallimann T, Hall CHT, Colgan SP, Glover LE. Creatine supplementation for patients with inflammatory bowel diseases. Nutrients 2021;13(5):1429. (Discussion of epithelial energy metabolism and GPR109A/butyrate signaling context.)
J-11 · Selenium
- Natural antioxidant substances improve oxidative stress and alleviate ulcerative colitis: a meta-analysis of randomized controlled trials. Sci Rep 2025. PMC12753649. (Includes selenium trials.)
J-12 · Vitamin C
- Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. Nutrients 2023. PMC10489664.
J-13 · Vitamin E
- Mirbagheri SA, Nezami BG, Assa S, Hajimahmoodi M. Rectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report. World J Gastroenterol 2008;14(39):5990–5995. (Open-label, 15 patients, 8,000 U/day enema for 12 weeks; Mayo DAI fell from 8 to 2.3; remission in 64%.)
J-14 · Vitamin B6
- Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. Nutrients 2023. PMC10489664.
J-15 · Vitamin K2
- Nakajima S, Iijima H, Egawa S, et al. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease. Nutrition 2011;27(10):1023–1028.
Visbiome / VSL#3 (closing table)
- Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009;7(11):1202–1209. (n = 147; 32.5% vs 10% reached a 50% UCDAI reduction at 6 weeks.)
- Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010;105(10):2218–2227. (n = 144.)
Tormentil (closing table)
- Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther 2002;16(2):197–205. (Tormentil among the herbs tested.)
- Huber R, Ditfurth AV, Amann F, et al. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol 2007;41(9):834–838. (16 patients; CAI fell from 8 to 4.5 at 2,400 mg/day; tannins not detected in serum.)
Fecal microbiota transplantation (honorable mentions)
- Březina J, Bajer L, Wohl P, et al. Fecal microbial transplantation versus mesalamine enema for treatment of active left-sided ulcerative colitis: results of a randomized controlled trial. J Clin Med 2021;10(13):2753.
Pouchitis note
- Refractory pouchitis improves after administration of the green tea polyphenol EGCG: a retrospective review. Int J Colorectal Dis 2017.
J-00 · J-00
- Nutrition, nutritional status, micronutrients deficiency, and disease course of inflammatory bowel disease. Nutrients 2023. PMC10489664. (Review of micronutrient deficiencies in IBD.)
Additives spotlight: emulsifiers, titanium dioxide, maltodextrin, carrageenan
- Chassaing B, Koren O, Goodrich JK, et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015;519(7541):92–96. (Carboxymethylcellulose and polysorbate-80 at 1% in drinking water.)
- Chassaing B, Van de Wiele T, De Bodt J, Marzorati M, Gewirtz AT. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut 2017;66(8):1414–1427.
- Chassaing B, Compher C, Bonhomme B, et al. Randomized controlled-feeding study of dietary emulsifier carboxymethylcellulose reveals detrimental impacts on the gut microbiota and metabolome. Gastroenterology 2022;162(3):743–756.
- The emulsifier carboxymethylcellulose induces more aggressive colitis in humanized mice with inflammatory bowel disease microbiota than polysorbate-80. Nutrients 2021. PMC8540676.
- Roberts CL, et al. Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010;59(10):1331–1339. (Polysorbate-80 increased E. coli translocation; cited in the Nutrients 2021 paper above.)
- Ruiz PA, Morón B, Becker HM, et al. Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome. Gut 2017;66(7):1216–1224. (Also found raised blood titanium in UC patients with active disease.)
- Nickerson KP, McDonald C. Crohn's disease-associated adherent-invasive Escherichia coli adhesion is enhanced by exposure to the ubiquitous dietary polysaccharide maltodextrin. PLoS One 2012;7(12):e52132.
- Bhattacharyya S, Shumard T, Xie H, et al. A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity. Nutr Healthy Aging 2017;4(2):181–192. (12 patients in remission; 3 of 5 given carrageenan relapsed vs 0 of 7.)
- Levine A, Rhodes JM, Lindsay JO, et al. Dietary guidance from the International Organization for the Study of Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2020;18(6):1381–1392.
- Laudisi F, Stolfi C, Monteleone G. Inflammatory bowel diseases and food additives: to add fuel on the flames! Nutrients 2019;11(5):1111.
- Nickerson KP, Chanin R, McDonald C. Deregulation of intestinal anti-microbial defense by the dietary additive, maltodextrin. Gut Microbes 2015;6(1):78–83.
Four diseases, one guide (front matter)
- Nguyen GC, Smalley WE, Vege SS, Carrasco-Labra A; Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the medical management of microscopic colitis. Gastroenterology 2016;150(1):242–246. (Budesonide first-line for induction and maintenance; budesonide over mesalamine, strong recommendation, high-quality evidence; suggests against probiotics for induction.)
- Miehlke S, Guagnozzi D, Zabana Y, et al. European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. United European Gastroenterol J 2021;9(1):13–37.
- Kafil TS, et al. Interventions for treating collagenous colitis. Cochrane Database Syst Rev 2017;11:CD003575. (Twelve RCTs, 476 participants; Boswellia serrata clinical response 44% vs 27%, RR 1.64, 95% CI 0.60–4.49, GRADE low.)
- Miehlke S, Verhaegh B, Tontini GE, Khalifa A, Heptner G, Villanacci V. Microscopic colitis: pathophysiology and clinical management. Lancet Gastroenterol Hepatol 2019;4(4):305–314.
A note on enemas, and the Briggs Protocol (Section L)
- Briggs M. Understanding the pathogenesis of inflammatory bowel diseases, and moving towards a "functional cure." Self-published paper, 2017; summarized as the Briggs Protocol at thepowerofpoop.com/briggs-protocol. (Not peer-reviewed; a patient-scientist's synthesis of the barrier-translocation model with a three-phase supplement and enema plan.)
- Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther 2012;35(3):327–334.
- Khan Z, Macdonald C, Wicks AC, et al. Use of the 'nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study. Aliment Pharmacol Ther 2002;16(11):1917–1922.
Vitamin C before exercise (my personal protocol, Section N)
- Ashton T, Young IS, Davison GW, et al. Exercise-induced endotoxemia: the effect of ascorbic acid supplementation. Free Radic Biol Med 2003;35(3):284–291. (Two weeks of 1,000 mg/day ascorbic acid blunted the rise in plasma endotoxin and lipid peroxidation after exhaustive exercise in healthy men.)
- Gordon BL, Galati JS, Yang S, Longman RS, Lukin D, Scherl EJ, Battat R. Vitamin C deficiency in inflammatory bowel disease: the forgotten micronutrient. Crohns Colitis 360 2020;2(1):otaa008.
Why a gut guide has a brain section (Section M)
- Bernstein CN, Singh S, Graff LA, Walker JR, Miller N, Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010;105(9):1994–2002. (Perceived stress and negative affect predicted symptomatic flares over three months.)
- Ananthakrishnan AN, Long MD, Martin CF, Sandler RS, Kappelman MD. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis. Clin Gastroenterol Hepatol 2013;11(8):965–971. (Sleep disturbance in quiescent Crohn's disease roughly doubled the odds of active disease at six months.)
- Felger JC, Treadway MT. Inflammation effects on motivation and motor activity: role of dopamine. Neuropsychopharmacology 2017;42(1):216–241.
- Nielsen PR, Benros ME, Dalsgaard S. Associations between autoimmune diseases and attention-deficit/hyperactivity disorder: a nationwide study. J Am Acad Child Adolesc Psychiatry 2017;56(3):234–240.e1.
- Irwin MR. Sleep and inflammation: partners in sickness and in health. Nat Rev Immunol 2019;19(11):702–715.
M-01 · M-01
- Ngan A, Conduit R. A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality. Phytother Res 2011;25(8):1153–1159.
- Shinjyo N, Waddell G, Green J. Valerian root in treating sleep problems and associated disorders: a systematic review and meta-analysis. J Evid Based Integr Med 2020;25:2515690X20967323.
- US Food and Drug Administration. Consumer advisory: kava-containing dietary supplements may be associated with severe liver injury. 2002.
M-02 · M-02
- Ernst E. Bach flower remedies: a systematic review of randomised clinical trials. Swiss Med Wkly 2010;140:w13079. (Seven trials; no effect beyond placebo.)
M-03 · M-03
- Hidese S, Ogawa S, Ota M, et al. Effects of L-theanine administration on stress-related symptoms and cognitive functions in healthy adults: a randomized controlled trial. Nutrients 2019;11(10):2362.
- Owen GN, Parnell H, De Bruin EA, Rycroft JA. The combined effects of L-theanine and caffeine on cognitive performance and mood. Nutr Neurosci 2008;11(4):193–198.
- Haskell CF, Kennedy DO, Milne AL, Wesnes KA, Scholey AB. The effects of L-theanine, caffeine and their combination on cognition and mood. Biol Psychol 2008;77(2):113–122.
M-04 · M-04
- Jongkees BJ, Hommel B, Kühn S, Colzato LS. Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands: a review. J Psychiatr Res 2015;70:50–57.
- Felger JC, Treadway MT. Inflammation effects on motivation and motor activity: role of dopamine. Neuropsychopharmacology 2017;42(1):216–241.
A word to the people this guide is for (front matter)
- Hracs L, Windsor JW, Gorospe J, et al.; Global IBD Research Group. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature 2025;642(8067):458–466. doi:10.1038/s41586-025-08940-0. (Reported prevalence: Olmsted County 0.12% in 1965 to 0.63% in 2019; Japan 0.067% in 2000 to 0.165% in 2016; Brazil 0.014% in 2000 to 0.1% in 2020.)
- Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18(1):56–66.
- GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017. Lancet Gastroenterol Hepatol 2020;5(1):17–30. (6.8 million cases in 2017.)
- Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open 2023;13(3):e065186. (Approximately 4.9 million cases in 2019; the GBD 2019 round revised earlier estimates downward.)
- Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017;390(10114):2769–2778.
Quercetin and the thyroid (A-02 caution)
- Giuliani C, Noguchi Y, Harii N, et al. The flavonoid quercetin regulates growth and gene expression in rat FRTL-5 thyroid cells. Endocrinology 2008;149(1):84–92.
- Giuliani C, Bucci I, Di Santo S, et al. The flavonoid quercetin inhibits thyroid-restricted genes expression and thyroid function. Food Chem Toxicol 2014;66:23–29. (Rats given 50 mg/kg/day intraperitoneally for 14 days had radioiodine uptake reduced to about half of control.)
- Giuliani C, Verrocchio S, Verginelli F, Bucci I, Grassadonia A, Napolitano G. Quercetin and thyroid. Antioxidants (Basel) 2024;13(10):1202. (Review: laboratory and animal evidence of thyroid disruption; no clinical trial of supplemental quercetin on human thyroid function.)
Vitamin B12 in men: the association behind the caution (Section J)
- Brasky TM, White E, Chen CL. Long-term, supplemental, one-carbon metabolism-related vitamin B use in relation to lung cancer risk in the Vitamins and Lifestyle (VITAL) cohort. J Clin Oncol 2017;35(30):3440–3448. (Observational cohort of 77,118 adults; individual-source B6 and B12 supplements, not multivitamins, associated with higher lung-cancer risk in men only; B12 above 55 mcg/day averaged over ten years, HR 1.98; the association was strongest in current smokers; no association in women.)
The most missing bacterium: the development pipeline (Section D)
- Guarino-Vignon P, et al. Faecalibacterium prausnitzii EXL01 for the maintenance of steroid-induced clinical response or remission in patients with Crohn's disease: a first in human trial. Nat Commun 2026. doi:10.1038/s41467-026-72375-y. (Open-label, single-arm, eight adults with mild-to-moderate Crohn's disease after corticosteroid-induced response or remission; oral EXL01 was well tolerated with no treatment-related adverse events; six completed, two discontinued for flare. ClinicalTrials.gov NCT05542355.)
- Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105(43):16731–16736.
Serum-derived bovine immunoglobulin as a medical food (A-04)
- EnteraGam (serum-derived bovine immunoglobulin/protein isolate) product information, Entera Health, updated February 2026. (A medical food intended for the dietary management of chronic diarrhea and loose stools, to be used under medical supervision; 5 g of SBI with 5 g dextrose per serving; not an FDA-approved drug for any disease.)
The multivitamin label, checked (Section J)
- Pure Encapsulations. O.N.E. Multivitamin supplement facts, Fullscript catalog listing, checked September 2026. (Vitamin B6 4 mg per capsule as pyridoxine HCl with 38% as pyridoxal 5'-phosphate; vitamin B12 500 mcg as methylcobalamin; vitamin D3 2,000 IU.)
Diet first (front matter)
- Lewis JD, Sandler RS, Brotherton C, et al.; DINE-CD Study Group. A randomized trial comparing the Specific Carbohydrate Diet to a Mediterranean diet in adults with Crohn's disease. Gastroenterology 2021;161(3):837–852. (n = 194, mild-to-moderate Crohn's disease; symptomatic remission at six weeks 46.5% on SCD versus 43.5% on the Mediterranean diet, not significantly different.)